Answers are grounded in this paper and cite their sources.
The diagnostic accuracy of MRI-TRUS fusion-guided prostate biopsy has not been widely studied, and there are no reports from Mexico. The aim of this study was to determine the diagnostic accuracy of MRI-TRUS fusion-guided biopsy in patients with suspected prostate cancer and histopathological examination. This diagnostic test study included men with suspected prostate cancer with elevated prostate-specific antigen (PSA) (>4 ng/ml) and/or an abnormal rectal examination who underwent MRI-TRUS fusion-guided biopsy. All prostate lesions were scored with the Prostate Imaging-Reporting and Data System (PI-RADS). Sensitivity, specificity, accuracy, PPV, and NPP were calculated based on histopathological confirmation. Thirty-five patients with suspected prostate cancer with a mean age of 69.5 9.6 years were included. Prostate cancer was histopathologically confirmed in 19 (90.5%) of 21 patients with PI-RADS 4 and one patient (100%) with PI-RADS 5. Clinically significant cancer was found in 20 (90.9%) of 22 cases with Gleason 7 (n = 17) and Gleason 8 (n = 3). The diagnostic accuracy of MRI-TRUS fusion-guided prostate biopsy was 87.8% (95% CI, 70.8-98.8). This report is the first in Mexico of experience with MRI-TRUS fusion-guided prostate biopsy in patients with suspected prostate cancer. This technique showed high diagnostic accuracy in patients with clinically significant prostate cancer.
No takes yet. Share an insight, caveat, or question.
Leon et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: